The main objective of this study is establish the performance of miR371 in management of testicular cancer
Age range
18 Years – 70 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
miR371 as a biomarker in testicular germ cell cancer at orchiectomy
Timeframe: 5 years
miR371 as a biomarker in testicular germ cell cancer at RPLND
Timeframe: 5 years
miR371 as a biomarker in testicular germ cell cancer during chemotherapy treatment
Timeframe: 5 years
miR371 as a biomarker in testicular germ cell cancer and detection of recurrence
Timeframe: 5 years
Mette Pernille Myklebust, PhD